Separately, SVB Leerink decreased their target price on shares of ContraFect from $14.00 to $9.00 and set an outperform rating for the company in a research note on Wednesday, February 16th.
Shares of NASDAQ CFRX opened at $3.83 on Monday. ContraFect has a 12 month low of $2.11 and a 12 month high of $4.76. The company has a 50 day simple moving average of $3.41 and a two-hundred day simple moving average of $3.29. The stock has a market cap of $150.65 million, a price-to-earnings ratio of -6.84 and a beta of 0.57.
Several institutional investors have recently added to or reduced their stakes in the company. Telemetry Investments L.L.C. boosted its position in shares of ContraFect by 2.4% during the 3rd quarter. Telemetry Investments L.L.C. now owns 134,382 shares of the biotechnology company’s stock valued at $544,000 after acquiring an additional 3,134 shares during the last quarter. Morgan Stanley lifted its position in shares of ContraFect by 10.5% during the second quarter. Morgan Stanley now owns 43,060 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 4,083 shares in the last quarter. BlackRock Inc. lifted its position in shares of ContraFect by 0.8% during the fourth quarter. BlackRock Inc. now owns 530,194 shares of the biotechnology company’s stock worth $1,395,000 after purchasing an additional 4,293 shares in the last quarter. WealthTrust Axiom LLC lifted its position in shares of ContraFect by 20.0% during the fourth quarter. WealthTrust Axiom LLC now owns 30,025 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Wedmont Private Capital acquired a new stake in shares of ContraFect during the fourth quarter worth about $25,000. 58.44% of the stock is owned by institutional investors and hedge funds.
About ContraFect (Get Rating)
ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins and Amurin Peptides.
- Get a free copy of the StockNews.com research report on ContraFect (CFRX)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Ross Stores On The Verge Of Major Rally
- Insiders Are Selling Palo Alto Networks
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.